Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | LTC4S | Q16873 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.36 |
| ▸ | ERAP1 | Q9NZ08 | 2/20 | 0.36 |
| ▸ | ESRRA | P11474 | 1/20 | 0.35 |
| ▸ | DHFR | P00374 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NQO2 | P16083 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596997 | 0.88 | MAPT (0.43) | MAPTHCRTR1HCRTR2FFAR1FFAR2 | |
| SCHEMBL6364181 | 0.86 | POLQ (0.41) | MAPTHCRTR1HCRTR2PTGDR2ERAP1 | |
| SCHEMBL13388545 | 0.86 | MAPT (0.43) | MAPTHCRTR1HCRTR2ERAP1DHFR | |
| SCHEMBL13388895 | 0.85 | MAPT (0.43) | MAPTHCRTR1HCRTR2LTC4SPTGDR2 | |
| SCHEMBL6249698 | 0.81 | MAPT (0.43) | MAPTHCRTR1HCRTR2ERAP1 | |
| SCHEMBL14760908 | 0.80 | MAPT (0.41) | MAPTHCRTR1HCRTR2PTGDR2ERAP1 | |
| SCHEMBL6258541 | 0.79 | SCN8A (0.40) | MAPTHCRTR1HCRTR2PTGDR2ERAP1 | |
| SCHEMBL13388527 | 0.79 | ALDH1A1 (0.39) | MAPT | |
| SCHEMBL1513789 | 0.79 | ERAP1 (0.47) | MAPTERAP1NQO2 | |
| SCHEMBL13388599 | 0.78 | EPAS1 (0.38) | MAPTHCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER HEALTHERCARE LLC (US) | 2012-10-25 | — | — | US | claimed |
| EP-1042305-A4 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER AG (US) | 2003-05-14 | — | — | EP | disclosed |
| EP-1042305-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | Bayer Corporation (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032463-A1 | INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | BAYER CORPORATION (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270878-A1 | INHIBITION OF P38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS | MAP2K2, MAPK1, MAP2K1 | MAPT 618/4885HCRTR1 4428/4885HCRTR2 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.